Table of Content

1 Neurological Drugs Market Overview
1.1 Product Overview and Scope of Neurological Drugs
1.2 Neurological Drugs Segment by Type
1.2.1 Global Neurological Drugs Market Value Comparison by Type (2024-2034)
1.2.2 Non-prescription drugs
1.2.3 Prescription
1.3 Neurological Drugs Segment by Application
1.3.1 Global Neurological Drugs Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Neurological Drugs Market Size Estimates and Forecasts
1.4.1 Global Neurological Drugs Revenue 2018-2034
1.4.2 Global Neurological Drugs Sales 2018-2034
1.4.3 Global Neurological Drugs Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Neurological Drugs Market Competition by Manufacturers
2.1 Global Neurological Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Neurological Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Neurological Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Neurological Drugs Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Neurological Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurological Drugs, Product Type & Application
2.7 Neurological Drugs Market Competitive Situation and Trends
2.7.1 Neurological Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neurological Drugs Players Market Share by Revenue
2.7.3 Global Neurological Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neurological Drugs Retrospective Market Scenario by Region
3.1 Global Neurological Drugs Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Neurological Drugs Global Neurological Drugs Sales by Region: 2018-2034
3.2.1 Global Neurological Drugs Sales by Region: 2018-2023
3.2.2 Global Neurological Drugs Sales by Region: 2024-2034
3.3 Global Neurological Drugs Global Neurological Drugs Revenue by Region: 2018-2034
3.3.1 Global Neurological Drugs Revenue by Region: 2018-2023
3.3.2 Global Neurological Drugs Revenue by Region: 2024-2034
3.4 North America Neurological Drugs Market Facts & Figures by Country
3.4.1 North America Neurological Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Neurological Drugs Sales by Country (2018-2034)
3.4.3 North America Neurological Drugs Revenue by Country (2018-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neurological Drugs Market Facts & Figures by Country
3.5.1 Europe Neurological Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Neurological Drugs Sales by Country (2018-2034)
3.5.3 Europe Neurological Drugs Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurological Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Neurological Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Neurological Drugs Sales by Country (2018-2034)
3.6.3 Asia Pacific Neurological Drugs Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Neurological Drugs Market Facts & Figures by Country
3.7.1 Latin America Neurological Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Neurological Drugs Sales by Country (2018-2034)
3.7.3 Latin America Neurological Drugs Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Neurological Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurological Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Neurological Drugs Sales by Country (2018-2034)
3.8.3 Middle East and Africa Neurological Drugs Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neurological Drugs Sales by Type (2018-2034)
4.1.1 Global Neurological Drugs Sales by Type (2018-2023)
4.1.2 Global Neurological Drugs Sales by Type (2024-2034)
4.1.3 Global Neurological Drugs Sales Market Share by Type (2018-2034)
4.2 Global Neurological Drugs Revenue by Type (2018-2034)
4.2.1 Global Neurological Drugs Revenue by Type (2018-2023)
4.2.2 Global Neurological Drugs Revenue by Type (2024-2034)
4.2.3 Global Neurological Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Neurological Drugs Price by Type (2018-2034)
5 Segment by Application
5.1 Global Neurological Drugs Sales by Application (2018-2034)
5.1.1 Global Neurological Drugs Sales by Application (2018-2023)
5.1.2 Global Neurological Drugs Sales by Application (2024-2034)
5.1.3 Global Neurological Drugs Sales Market Share by Application (2018-2034)
5.2 Global Neurological Drugs Revenue by Application (2018-2034)
5.2.1 Global Neurological Drugs Revenue by Application (2018-2023)
5.2.2 Global Neurological Drugs Revenue by Application (2024-2034)
5.2.3 Global Neurological Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Neurological Drugs Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Neurological Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Corporation Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Ely Lilly Neurological Drugs Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Corporation Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Actavis Neurological Drugs Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Mylan Neurological Drugs Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Randox
6.5.1 Randox Corporation Information
6.5.2 Randox Description and Business Overview
6.5.3 Randox Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Randox Neurological Drugs Product Portfolio
6.5.5 Randox Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Corporation Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Intellipharmaceutics Neurological Drugs Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.6.1 Astrazeneca Corporation Information
6.6.2 Astrazeneca Description and Business Overview
6.6.3 Astrazeneca Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Astrazeneca Neurological Drugs Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Corporation Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Lundbeck Neurological Drugs Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Corporation Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Allergan Neurological Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 GSK Neurological Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Corporation Information
6.11.2 Otsuka Pharmaceutical Neurological Drugs Description and Business Overview
6.11.3 Otsuka Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Otsuka Pharmaceutical Neurological Drugs Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Corporation Information
6.12.2 Takeda Neurological Drugs Description and Business Overview
6.12.3 Takeda Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Takeda Neurological Drugs Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 NHU Group
6.13.1 NHU Group Corporation Information
6.13.2 NHU Group Neurological Drugs Description and Business Overview
6.13.3 NHU Group Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 NHU Group Neurological Drugs Product Portfolio
6.13.5 NHU Group Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Corporation Information
6.14.2 Shionogi Neurological Drugs Description and Business Overview
6.14.3 Shionogi Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Shionogi Neurological Drugs Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Corporation Information
6.15.2 APOTEX Neurological Drugs Description and Business Overview
6.15.3 APOTEX Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 APOTEX Neurological Drugs Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 North China Pharmaceutical
6.16.1 North China Pharmaceutical Corporation Information
6.16.2 North China Pharmaceutical Neurological Drugs Description and Business Overview
6.16.3 North China Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.16.4 North China Pharmaceutical Neurological Drugs Product Portfolio
6.16.5 North China Pharmaceutical Recent Developments/Updates
6.17 Harbin Pharmaceutical Co., Ltd.
6.17.1 Harbin Pharmaceutical Co., Ltd. Corporation Information
6.17.2 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Description and Business Overview
6.17.3 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolio
6.17.5 Harbin Pharmaceutical Co., Ltd. Recent Developments/Updates
6.18 Lukang Pharmaceutical
6.18.1 Lukang Pharmaceutical Corporation Information
6.18.2 Lukang Pharmaceutical Neurological Drugs Description and Business Overview
6.18.3 Lukang Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Lukang Pharmaceutical Neurological Drugs Product Portfolio
6.18.5 Lukang Pharmaceutical Recent Developments/Updates
6.19 Kelun Pharmaceutical
6.19.1 Kelun Pharmaceutical Corporation Information
6.19.2 Kelun Pharmaceutical Neurological Drugs Description and Business Overview
6.19.3 Kelun Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Kelun Pharmaceutical Neurological Drugs Product Portfolio
6.19.5 Kelun Pharmaceutical Recent Developments/Updates
6.20 Kehua Biology
6.20.1 Kehua Biology Corporation Information
6.20.2 Kehua Biology Neurological Drugs Description and Business Overview
6.20.3 Kehua Biology Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Kehua Biology Neurological Drugs Product Portfolio
6.20.5 Kehua Biology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurological Drugs Industry Chain Analysis
7.2 Neurological Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurological Drugs Production Mode & Process
7.4 Neurological Drugs Sales and Marketing
7.4.1 Neurological Drugs Sales Channels
7.4.2 Neurological Drugs Distributors
7.5 Neurological Drugs Customers
8 Neurological Drugs Market Dynamics
8.1 Neurological Drugs Industry Trends
8.2 Neurological Drugs Market Drivers
8.3 Neurological Drugs Market Challenges
8.4 Neurological Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Neurological Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Neurological Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Neurological Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Neurological Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Neurological Drugs Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Neurological Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Neurological Drugs Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Neurological Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Neurological Drugs, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Neurological Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Neurological Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Neurological Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Neurological Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Neurological Drugs Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Neurological Drugs Sales by Region (2018-2023) & (K Units)
Table 18. Global Neurological Drugs Sales Market Share by Region (2018-2023)
Table 19. Global Neurological Drugs Sales by Region (2024-2034) & (K Units)
Table 20. Global Neurological Drugs Sales Market Share by Region (2024-2034)
Table 21. Global Neurological Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Neurological Drugs Revenue Market Share by Region (2018-2023)
Table 23. Global Neurological Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Neurological Drugs Revenue Market Share by Region (2024-2034)
Table 25. North America Neurological Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Neurological Drugs Sales by Country (2018-2023) & (K Units)
Table 27. North America Neurological Drugs Sales by Country (2024-2034) & (K Units)
Table 28. North America Neurological Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Neurological Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Neurological Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Neurological Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Europe Neurological Drugs Sales by Country (2024-2034) & (K Units)
Table 33. Europe Neurological Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Neurological Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Neurological Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Neurological Drugs Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Neurological Drugs Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Neurological Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Neurological Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Neurological Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Neurological Drugs Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Neurological Drugs Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Neurological Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Neurological Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Neurological Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Neurological Drugs Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Neurological Drugs Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Neurological Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Neurological Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Neurological Drugs Sales (K Units) by Type (2018-2023)
Table 51. Global Neurological Drugs Sales (K Units) by Type (2024-2034)
Table 52. Global Neurological Drugs Sales Market Share by Type (2018-2023)
Table 53. Global Neurological Drugs Sales Market Share by Type (2024-2034)
Table 54. Global Neurological Drugs Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Neurological Drugs Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Neurological Drugs Revenue Market Share by Type (2018-2023)
Table 57. Global Neurological Drugs Revenue Market Share by Type (2024-2034)
Table 58. Global Neurological Drugs Price (US$/Unit) by Type (2018-2023)
Table 59. Global Neurological Drugs Price (US$/Unit) by Type (2024-2034)
Table 60. Global Neurological Drugs Sales (K Units) by Application (2018-2023)
Table 61. Global Neurological Drugs Sales (K Units) by Application (2024-2034)
Table 62. Global Neurological Drugs Sales Market Share by Application (2018-2023)
Table 63. Global Neurological Drugs Sales Market Share by Application (2024-2034)
Table 64. Global Neurological Drugs Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Neurological Drugs Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Neurological Drugs Revenue Market Share by Application (2018-2023)
Table 67. Global Neurological Drugs Revenue Market Share by Application (2024-2034)
Table 68. Global Neurological Drugs Price (US$/Unit) by Application (2018-2023)
Table 69. Global Neurological Drugs Price (US$/Unit) by Application (2024-2034)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Pfizer Neurological Drugs Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Ely Lilly Corporation Information
Table 76. Ely Lilly Description and Business Overview
Table 77. Ely Lilly Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Ely Lilly Neurological Drugs Product
Table 79. Ely Lilly Recent Developments/Updates
Table 80. Actavis Corporation Information
Table 81. Actavis Description and Business Overview
Table 82. Actavis Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Actavis Neurological Drugs Product
Table 84. Actavis Recent Developments/Updates
Table 85. Mylan Corporation Information
Table 86. Mylan Description and Business Overview
Table 87. Mylan Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Mylan Neurological Drugs Product
Table 89. Mylan Recent Developments/Updates
Table 90. Randox Corporation Information
Table 91. Randox Description and Business Overview
Table 92. Randox Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Randox Neurological Drugs Product
Table 94. Randox Recent Developments/Updates
Table 95. Intellipharmaceutics Corporation Information
Table 96. Intellipharmaceutics Description and Business Overview
Table 97. Intellipharmaceutics Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Intellipharmaceutics Neurological Drugs Product
Table 99. Intellipharmaceutics Recent Developments/Updates
Table 100. Astrazeneca Corporation Information
Table 101. Astrazeneca Description and Business Overview
Table 102. Astrazeneca Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Astrazeneca Neurological Drugs Product
Table 104. Astrazeneca Recent Developments/Updates
Table 105. Lundbeck Corporation Information
Table 106. Lundbeck Description and Business Overview
Table 107. Lundbeck Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Lundbeck Neurological Drugs Product
Table 109. Lundbeck Recent Developments/Updates
Table 110. Allergan Corporation Information
Table 111. Allergan Description and Business Overview
Table 112. Allergan Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Allergan Neurological Drugs Product
Table 114. Allergan Recent Developments/Updates
Table 115. GSK Corporation Information
Table 116. GSK Description and Business Overview
Table 117. GSK Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. GSK Neurological Drugs Product
Table 119. GSK Recent Developments/Updates
Table 120. Otsuka Pharmaceutical Corporation Information
Table 121. Otsuka Pharmaceutical Description and Business Overview
Table 122. Otsuka Pharmaceutical Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Otsuka Pharmaceutical Neurological Drugs Product
Table 124. Otsuka Pharmaceutical Recent Developments/Updates
Table 125. Takeda Corporation Information
Table 126. Takeda Description and Business Overview
Table 127. Takeda Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Takeda Neurological Drugs Product
Table 129. Takeda Recent Developments/Updates
Table 130. NHU Group Corporation Information
Table 131. NHU Group Description and Business Overview
Table 132. NHU Group Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. NHU Group Neurological Drugs Product
Table 134. NHU Group Recent Developments/Updates
Table 135. Shionogi Corporation Information
Table 136. Shionogi Description and Business Overview
Table 137. Shionogi Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Shionogi Neurological Drugs Product
Table 139. Shionogi Recent Developments/Updates
Table 140. APOTEX Corporation Information
Table 141. APOTEX Description and Business Overview
Table 142. APOTEX Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. APOTEX Neurological Drugs Product
Table 144. APOTEX Recent Developments/Updates
Table 145. North China Pharmaceutical Corporation Information
Table 146. North China Pharmaceutical Description and Business Overview
Table 147. North China Pharmaceutical Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. North China Pharmaceutical Neurological Drugs Product
Table 149. North China Pharmaceutical Recent Developments/Updates
Table 150. Harbin Pharmaceutical Co., Ltd. Corporation Information
Table 151. Harbin Pharmaceutical Co., Ltd. Description and Business Overview
Table 152. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product
Table 154. Harbin Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 155. Lukang Pharmaceutical Corporation Information
Table 156. Lukang Pharmaceutical Description and Business Overview
Table 157. Lukang Pharmaceutical Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. Lukang Pharmaceutical Neurological Drugs Product
Table 159. Lukang Pharmaceutical Recent Developments/Updates
Table 160. Kelun Pharmaceutical Corporation Information
Table 161. Kelun Pharmaceutical Description and Business Overview
Table 162. Kelun Pharmaceutical Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 163. Kelun Pharmaceutical Neurological Drugs Product
Table 164. Kelun Pharmaceutical Recent Developments/Updates
Table 165. Kehua Biology Corporation Information
Table 166. Kehua Biology Description and Business Overview
Table 167. Kehua Biology Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 168. Kehua Biology Neurological Drugs Product
Table 169. Kehua Biology Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Neurological Drugs Distributors List
Table 173. Neurological Drugs Customers List
Table 174. Neurological Drugs Market Trends
Table 175. Neurological Drugs Market Drivers
Table 176. Neurological Drugs Market Challenges
Table 177. Neurological Drugs Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Neurological Drugs
Figure 2. Global Neurological Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Neurological Drugs Market Share by Type in 2024 & 2034
Figure 4. Non-prescription drugs Product Picture
Figure 5. Prescription Product Picture
Figure 6. Global Neurological Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Neurological Drugs Market Share by Application in 2024 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Neurological Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 11. Global Neurological Drugs Market Size (2018-2034) & (US$ Million)
Figure 12. Global Neurological Drugs Sales (2018-2034) & (K Units)
Figure 13. Global Neurological Drugs Average Price (US$/Unit) & (2018-2034)
Figure 14. Neurological Drugs Report Years Considered
Figure 15. Neurological Drugs Sales Share by Manufacturers in 2024
Figure 16. Global Neurological Drugs Revenue Share by Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Neurological Drugs Players: Market Share by Revenue in 2024
Figure 18. Neurological Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 19. Global Neurological Drugs Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 20. North America Neurological Drugs Sales Market Share by Country (2018-2034)
Figure 21. North America Neurological Drugs Revenue Market Share by Country (2018-2034)
Figure 22. United States Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 23. Canada Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 24. Europe Neurological Drugs Sales Market Share by Country (2018-2034)
Figure 25. Europe Neurological Drugs Revenue Market Share by Country (2018-2034)
Figure 26. Germany Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 27. France Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 28. U.K. Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. Italy Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. Russia Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Asia Pacific Neurological Drugs Sales Market Share by Region (2018-2034)
Figure 32. Asia Pacific Neurological Drugs Revenue Market Share by Region (2018-2034)
Figure 33. China Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Japan Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. South Korea Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. India Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. Australia Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. China Taiwan Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Southeast Asia Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. Latin America Neurological Drugs Sales Market Share by Country (2018-2034)
Figure 41. Latin America Neurological Drugs Revenue Market Share by Country (2018-2034)
Figure 42. Mexico Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Brazil Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Argentina Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Colombia Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Middle East & Africa Neurological Drugs Sales Market Share by Country (2018-2034)
Figure 47. Middle East & Africa Neurological Drugs Revenue Market Share by Country (2018-2034)
Figure 48. Turkey Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Saudi Arabia Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. UAE Neurological Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Global Sales Market Share of Neurological Drugs by Type (2018-2034)
Figure 52. Global Revenue Market Share of Neurological Drugs by Type (2018-2034)
Figure 53. Global Neurological Drugs Price (US$/Unit) by Type (2018-2034)
Figure 54. Global Sales Market Share of Neurological Drugs by Application (2018-2034)
Figure 55. Global Revenue Market Share of Neurological Drugs by Application (2018-2034)
Figure 56. Global Neurological Drugs Price (US$/Unit) by Application (2018-2034)
Figure 57. Neurological Drugs Value Chain
Figure 58. Neurological Drugs Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed